Data/hora: 05/06/2024 17:02:25

Provedor de dados: 	42	
País: 	Brazil	
Título: 	Pertuzumab and trastuzumab: the rationale way to synergy	
Autores: 	RICHARD,SANDRINE; SELLE,FRÉDÉRIC; LOTZ,JEAN-PIERRE; KHALIL,AHMED; GLIGOROV,JOSEPH; SOARES,DANIELE G.	
Data: 	2016-01-01	
Ano: 	2016	
Palavras-chave: 	Breast cancer; Dimerization; HER2/3; Monoclonal antibody; Pertuzumab; Trastuzumab.	
Resumo: 	ABSTRACT It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways. Pertuzumab combined with trastuzumab plus docetaxel was approved for the first-line treatment of patients with HER2-positive metastatic breast cancer and is currently used as a standard of care in this indication. In the neoadjuvant setting, the drug was granted FDA-accelerated approval in 2013. Pertuzumab is also being evaluated in the adjuvant setting. The potential of pertuzumab relies in the dual complete blockade of the HER2/3 axis when administered with trastuzumab. This paper synthetises preclinical and clinical data on pertuzumab and highlights the mechanisms underlying the synergistic activity of the combination pertuzumab-trastuzumab which are essentially due to their complementary mode of action.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652016000200565	
Editor: 	Academia Brasileira de Ciências	
Relação: 	10.1590/0001-3765201620150178	
Formato: 	text/html	
Fonte: 	Anais da Academia Brasileira de Ciências  v.88 suppl.1 2016	
Fonte: 	info:eu-repo/semantics/openAccess